
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc has made significant advancements in its drug development programs for diabetes and obesity, which are supported by promising Phase II results for icovamenib and the initiation of a Phase I trial for BMF-650. Financially, the company has demonstrated improved efficiency, with a narrowed net loss of $61.8 million and reduced R&D expenses, indicating a more manageable cost structure as it focuses on its core metabolic assets. The positive trajectory of clinical data, including durable glycemic benefits and favorable safety profiles, suggests a solid foundation for upcoming data readouts in 2026, bolstering the outlook for the company's stock.
Bears say
Biomea Fusion Inc. has reported a significant decrease in research and development expenses, from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns about the viability and progress of its drug candidate programs. Additionally, general and administrative expenses have also declined, from $6.8 million to $4.2 million, potentially indicating tightening operational budgets amid financial pressures. The reduction in price target from $16.00 to $12.00 reflects an overall negative sentiment regarding the company's financial outlook and the efficacy of its ongoing clinical trials for diabetes and obesity treatments.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares